V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)

PHASE4CompletedINTERVENTIONAL

Enrollment

1,030

Participants

Timeline

Start Date

November 25, 2011

Primary Completion Date

August 27, 2016

Study Completion Date

August 27, 2016

Conditions

Cervical CancerCervical Intraepithelial NeoplasiaAdenocarcinoma in Situ

Interventions

BIOLOGICAL

V501

HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01544478 - V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) | Biotech Hunter | Biotech Hunter